ArticleOncogene2004
Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity.
Article in Oncogene, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Pooled it
- Critical Roles of SRC-3 in the Development and Progression of Breast Cancer, Rendering It a Prospective Clinical Target.Cancers · 2023Review
- AIB1/SRC-3/NCOA3 function in estrogen receptor alpha positive breast cancer.Frontiers in endocrinology · 2023Review
- SRC-3, a Steroid Receptor Coactivator: Implication in Cancer.International journal of molecular sciences · 2021Review
- Molecular Mechanisms of Endocrine Resistance in Estrogen-Positive Breast Cancer.Frontiers in endocrinology · 2021Review
- AFF3 upregulation mediates tamoxifen resistance in breast cancers.Journal of experimental & clinical cancer research : CR · 2018Article
- Taiman acts as a coactivator of Yorkie in the Hippo pathway to promote tissue growth and intestinal regeneration.Cell discovery · 2016Article
- MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Regulation of HER2 oncogene transcription by a multifunctional coactivator/corepressor complex.Molecular endocrinology (Baltimore, Md.) · 2014Article
- bHLH-PAS proteins in cancer.Nature reviews. Cancer · 2013Review
- The role of AIB1 in breast cancer.Oncology letters · 2012Article
- Role of the nuclear receptor coactivator AIB1-Delta4 splice variant in the control of gene transcription.The Journal of biological chemistry · 2011Article
- Assessing estrogen signaling aberrations in breast cancer risk using genetically engineered mouse models.Annals of the New York Academy of Sciences · 2011Review
- Altered AIB1 or AIB1Δ3 expression impacts ERα effects on mammary gland stromal and epithelial content.Molecular endocrinology (Baltimore, Md.) · 2011Article
- Minireview: steroid receptor coactivator-3: a multifarious coregulator in mammary gland metastasis.Endocrinology · 2011Review
- Steroid receptor coactivator (SRC) family: masters of systems biology.The Journal of biological chemistry · 2010Review
- A PAK-activated linker for EGFR and FAK.Developmental cell · 2010Article
- SRC-3Delta4 mediates the interaction of EGFR with FAK to promote cell migration.Molecular cell · 2010Article
- The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer.Breast cancer research and treatment · 2009Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
The nuclear receptor coactivator amplified in breast cancer 1 (AIB1) and its more active isoform AIB1-Delta3 are overexpressed in breast cancer and preneoplastic breast tissue. However, the impact of these proteins on the transcriptional activity of natural estrogens or selective estrogen receptor modulators (SERMs) has not been determined. Here we show that AIB1-Delta3 causes a significant increase in the efficacy of 17beta-estradiol at both estrogen receptor-alpha (ER-alpha) and ER-beta in ovarian, breast and endometrial cancer cell lines. AIB1-Delta3 also significantly increased the efficacy of the natural estrogen genistein at both ER-alpha and ER-beta, whereas AIB1 had no effect on either the potency or efficacy of genistein at either receptor. The estrogenic efficacy of the partial agonist tamoxifen was significantly increased in all cell lines at ER-alpha by overexpression of AIB1-Delta3 both on transfected and endogenous estrogen responsive genes. In contrast, overexpression of AIB1 or AIB1-Delta3 had no effect on the potency or efficacy of the SERM raloxifene. We conclude that overexpression of the AIB1-Delta3 isoform will increase the estrogenicity of a variety of natural and pharmacologic compounds in tissues that develop hormone-dependent neoplasias and overexpression of these cofactors may be a contributing factor to the hormone-driven development of neoplasia and to antiestrogen resistance of breast cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.